Cardiac Pathways Receives CE Mark for Its Trio/Ensemble Catheters for Diagnosing Irregular Heart Rhythms.SUNNYVALE, Calif.--(BW HealthWire)--Aug. 3, 1998--Cardiac Pathways Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :CPWY), a developer of minimally invasive, cost-effective systems for diagnosing and treating abnormally rapid heart rhythms, today announced that it has received the CE mark for its Trio/Ensemble(R) diagnostic catheters, allowing sales to commence in Southern Europe. The Trio/Ensemble catheters are used for electrophysiological diagnostic mapping of supraventricular tachycardia supraventricular tachycardia n. Abbr. SVT A tachycardia that originates above the ventricles of the heart, as in the atria or the atrioventricular node. (SVT SVT supraventricular tachycardia. SVT abbr. supraventricular tachycardia SVT Supraventricular tachycardia, see there ), a congenital, rapid heart rhythm that originates above the ventricles Ventricles The two chambers of the heart that are involved in pumping blood. The right ventricle pumps blood into the lungs to receive oxygen. The left ventricle pumps blood into the circulation of the body to deliver oxygen to all of the body's organs and tissues. in the heart. Using the Trio/Ensemble diagnostic catheters, the electrophysiologist is able to place three catheters through a single patient introduction site rather than having to use three separate introduction sites. In this way, the Trio/Ensemble provides the electrophysiologist with an overall tool to assess electrical conduction between the atria Atria The heart has four chambers. The right and left atria are at the top of the heart and receive returning blood from the veins. The right and left ventricles are at the bottom of the heart and act as the body's main pumps. and the ventricle ventricle /ven·tri·cle/ (ven´tri-k'l) a small cavity or chamber, as in the brain or heart.ventric´ular ventricle of Arantius the rhomboid fossa, especially its lower end. . Once the SVT is mapped, it can readily be treated using standard radiofrequency (RF) catheter ablation Catheter Ablation Definition Catheter ablation of an irregular heartbeat involves having a tube (a catheter) inserted into the heart through which electrical energy is sent to either reset the heartbeat or stop the heart from beating so a mechanical techniques to neutralize the heart tissue responsible for the abnormal heart rhythm. The company believes this treatment option will become the therapy of choice for SVT over antiarrhythmic drugs, since the drugs do not successfully control SVT in many patients and often cause undesirable side effects. Company president and chief executive officer, William Starling starling, any of a group of originally Old World birds that have become distributed worldwide. Starlings were brought to New York in 1890; since then the common starling (Sturnus vulgaris) has spread throughout North America. , stated, "I am pleased that we have been able to quickly build Cardiac Pathways' product family of mapping and ablation systems offered in the European Market. Our Trio/Ensemble catheters are the company's third product to obtain the CE Mark approval this year, complementing our Radii-T(R) ablation catheter and Chilli(R) Cooled Ablation System." Cardiac Pathways designs, develops and manufactures minimally invasive systems to diagnose and treat cardiac tachyarrhythmias (abnormally rapid heart rhythms). The company is developing products designed to provide integrated system solutions for the improved diagnosis and treatment of ventricular tachycardia and atrial fibrillation, two of the most serious and prevalent types of heart rhythm disturbances. This release contains certain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the progress of the company's actions relating to regulatory matters, marketing and sales activities, particularly in Europe, the extent to which the company's products gain market acceptance, particularly in Europe, and competitive developments.
CONTACT: Cardiac Pathways Corp.
David W. Gryska, 408/737-0505
|
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion